Dofetilide for atrial fibrillation.
D000889:Anti-Arrhythmia Agents / Q000009:adverse effects / Q000627:therapeutic use*; D000890:Anti-Infective Agents / Q000494:pharmacology; D000892:Anti-Infective Agents, Urinary / Q000494:pharmacology; D000897:Anti-Ulcer Agents / Q000494:pharmacology; D000935:Antifungal Agents / Q000494:pharmacology; D001281:Atrial Fibrillation / Q000188:drug therapy*; D002927:Cimetidine / Q000494:pharmacology; D002986:Clinical Trials as Topic; D004305:Dose-Response Relationship, Drug; D004347:Drug Interactions; D006801:Humans; D007654:Ketoconazole / Q000494:pharmacology; D010627:Phenethylamines / Q000009:adverse effects / Q000627:therapeutic use*; D026902:Potassium Channel Blockers; D013420:Sulfamethoxazole / Q000494:pharmacology; D013449:Sulfonamides / Q000009:adverse effects / Q000627:therapeutic use*; D016171:Torsades de Pointes / Q000139:chemically induced / Q000517:prevention & control; D014295:Trimethoprim / Q000494:pharmacology*
D000889:Anti-Arrhythmia Agents; D000890:Anti-Infective Agents; D000892:Anti-Infective Agents, Urinary; D000897:Anti-Ulcer Agents; D000935:Antifungal Agents; D010627:Phenethylamines; D026902:Potassium Channel Blockers; D013449:Sulfonamides; D002927:Cimetidine; D014295:Trimethoprim; D013420:Sulfamethoxazole; C063533:dofetilide; D007654:Ketoconazole